Myriad: Marching in on BRCA test patents would be 'inappropriate'
This article was originally published in Scrip
Executive Summary
Even though the US Supreme Court's 13 June unanimous decision declaring isolated DNA not patent eligible was expected to open the door for cheaper alternatives to Myriad Genetics' BRACAnalysis ovarian and breast cancer diagnostic, the Salt Lake City-based company has taken legal action against its first two competitors – prompting a US lawmaker to call on the National Institutes of Health (NIH) to come marching in.